To clarify the clinicopathological characteristics of adenocarcinoma of the gastric cardia (AGC), including its association with Barrett’s esophagus and intestinal metaplasia, 49 surgically resected early AGCs (EAGCs) were examined clinicopathologically, histopathologically, histochemically, and immunohistochemically. The clinicopathological characteristics of the patients with EAGC were compared with those of 293 patients with early adenocarcinoma of the distal stomach (EADS) and 7 patients with early adenocarcinoma of the esophagus (EAE). Histochemical staining with paradoxical concanavalin A (ConA) and immunohistochemical staining with monoclonal antibodies 45M1, Ccp58, and 56C6 were performed to investigate the differentiation phenotype of the tumor. ConA and 45M1 were used for markers of the gastric phenotype, and Ccp58 and 56C6 were used for markers of the intestinal phenotype. EAGC was associated with a higher mean age (p < 0.0001), a higher male-to-female ratio (p < 0.05), a higher incidence of elevated-type tumors (p < 0.0001), a higher incidence of differentiated-type tumors (p < 0.0001), and greater depth of invasion (p < 0.05) compared with EADS. EAE was associated with a higher incidence of elevated-type tumors (p < 0.001), a higher incidence of differentiated-type tumors (p < 0.05), and larger tumor size (p < 0.05) compared with EADS. The prevalence of Barrett’s esophagus in patients with EAGC was significantly lower than in patients with EAE (10.2%, 5/49 patients vs. 100%, 7/7; p < 0.0001). The prevalence of intestinal (Barrett’s) metaplasia in surrounding non-neoplastic mucosa in patients with EAGC was significantly lower than in patients with EADS or EAE (36.7%, 18/49 patients vs. 72.0%, 211/293 and 85.7%, 6/7; p < 0.0001 and p < 0.05, respectively). EAGC was associated with a higher incidence of tumors that reacted positively for gastric phenotype markers alone than EADS (32.7%, 16/49 cases vs. 17.1%, 50/293; p < 0.05) and a lower incidence of tumors that reacted positively for both gastric and intestinal markers than EADS or EAE (40.8%, 20/49 cases vs. 59.7%, 175/293 and 85.7%, 6/7; p < 0.05, respectively). Our findings indicate that AGC forms a specific category different from both adenocarcinoma of the distal stomach and esophagus in terms of association with Barrett’s esophagus or intestinal metaplasia, and the differentiation phenotype of the tumor.

Keywords:
Adenocarcinoma, early, Barrett’s esophagus, Gastric/intestinal marker, Gastric cardia, Intestinal metaplasia
1.
Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184–197.
2.
Boring CC, Squires TS, Tong T: Cancer statistics, 1991. CA Cancer J Clin 1991;41:19–36.
3.
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–1289.
4.
Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510–513.
5.
MacDonald WC, MacDonald JB: Adenocarcinoma of esophagus and/or gastric cardia. Cancer 1987;60:1094–1098.
6.
Hamilton SR, Smith RR, Cameron JL: Prevalence and characteristics of Barrett’s esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988;19:942–948.
7.
Kalish RJ, Clancy PE, Orringer MB, Appleman HD: Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and in the gastric cardia. Gastroenterology 1984;86:461–467.
8.
Wang HH, Antonioli DA, Goldman H: Comparative features of esophageal and gastric adenocarcinomas: Recent changes in type and frequency. Hum Pathol 1986;17:482–487.
9.
Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, Hinder RA, Bremner CG, DeMeester TR: Is Barrett’s metaplasia the source of adenocarcinoma of the cardia? Arch Surg 1994;129:609–614.
10.
Siewert JR, Stein HJ: Carcinoma of the cardia: Carcinoma of the gastroesophageal junction – Classification, pathology and extent of resection. Dis Esophagus 1996;9:173–182.
11.
Cameron AJ, Lomboy CL, Pera M, Carpenter HA: Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 1995;109:1541–1546.
12.
Spechler SJ, Robbins AH, Runins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM: Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology 1984;87:927–933.
13.
Cameron AJ, Ott BJ, Patne WS: The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 1985;313:857–858.
14.
Paull A, Treier JS, Dalton MD, Camp RC, Loeb P, Goyal RK: The histologic spectrum of Barrett’s esophagus. N Engl J Med 1976;295:476–480.
15.
Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR: Barrett’s esophagus: Comparison of benign and malignant cases. Ann Surg 1983;198:554–566.
16.
Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JC: Barrett’s esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249–1256.
17.
van Sandick JW, van Lanschot JJB, ten Kate FJW, Offerhaus GJA, Fockens P, Tytgat GNJ, Obertop H: Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: Implications for therapeutic decision making. Cancer 2000;88:2429–2437.
18.
Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, Alfieri R, Bonavina L, Peracchia A, Ancona E: Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520–2528.
19.
Tatematsu M, Hasegawa R, Ogawa K, Kato T, Ichinose M, Miki K, Ito N: Histogenesis of human stomach cancers based on assessment of differentiation. J Clin Gastroenterol 1992;1(suppl 1): S1–S7.
20.
Egashira Y, Shimoda T, Ikegami M: Mucin histochemical analysis of minute gastric differentiated adenocarcinoma. Pathol Int 1999;49:55–61.
21.
Sasaki I, Yao T, Nawata H, Tsunehoshi M: Minute gastric carcinoma of differentiated type with special reference to the significance of intestinal metaplasia, proliferative zone, and p53 protein during tumor development. Cancer 1999;85:1719–1729.
22.
Yoshino T, Shimoda T, Saito A, Nakanishi Y, Tajima Y, Shirasu T, Miura S: Macroscopic features of differentiated adenocarcinoma with gastric or intestinal phenotype expression in early gastric cancer (in Japanese with English abstract). Stomach Intestine 1999;34:513–525.
23.
Tajima Y, Shimoda T, Nakanishi Y, Ikegami M, Kusano M: Histological, mucin histochemical and immunohistochemical study of Barrett’s epithelium and adenocarcinoma (in Japanese with English abstract). Stomach Intestine 1999;34:141–153.
24.
Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, ed 1. Tokyo, Kanehara, 1995.
25.
Takubo K, Sasajima K, Yamashita K, Tanaka Y, Fujita K: Double muscularis mucosae in Barrett’s esophagus. Hum Pathol 1991;22:1158–1161.
26.
Nakamura K, Sugano H, Takagi K: Carcinoma of the stomach in incipient phase: Its histogenesis and histological appearances. Jpn J Cancer Res 1968;59:251–258.
27.
Bara J, Gautier R, Mouradian P, Decaens C, Daher N: Oncofetal mucin M1 epitope family: Characterization and expression during colonic carcinogenesis. Int J Cancer 1991;47:304–310.
28.
Gum JR, Byrd JC, Hicks JW, Toribara NW, Lamport DT, Kim YS: Molecular cloning of human intestinal mucin cDNAs. J Biol Chem 1989;264:6480–6487.
29.
Kim YS, Gum JR: Diversity of mucin genes, structure, function, and expression. Gastroenterology 1995;109:999–1013.
30.
Ronco P, Allegri L, Melcion C, Pirotsky E, Appay MD, Bariety J, Pontillon F, Verroust P: A monoclonal antibody to brush border and passive nephritis. Clin Exp Immunol 1984;55:319–332.
31.
Trejdosiewicz LK, Malizia G, Oakes J, Losowsky MS, Janossy G: Expression of common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease. J Clin Pathol 1985;38:1002–1006.
32.
Hsu SM, Raine L, Fanger H: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577–580.
33.
Shi SR, Key ME, Karla KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–748.
34.
Riddell RH: Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol 1996;91:853–863.
35.
Saito K, Shimoda T: Histogenesis and early invasion of gastric cancer. Acta Pathol Jpn 1986;36:1307–1318.
36.
Tahara E: Genetic alternations in human gastrointestinal cancers. Cancer 1995;75:1410–1417.
37.
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand A 1965;64:31–49.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.